Study of Edoxaban for anti-coagulation after Watchman implant
Matthew J Price, M.D.
This study will evaluate the safety and effectiveness of 6 weeks of anticoagulation therapy with Edoxaban followed by therapy with aspirin and clopidogrel for 6 months in patients who have had a WATCHMAN device implanted for closure of the left atrial appendage (LAA). Patients will have a follow-up visit at 6 weeks post-LAA closure and one follow-up phone call at 6 months.
Have documented non-valvular Atrial Fibrillation
Be scheduled or planning to have a WATCHMAN device implanted for LAA closure
Meet all other eligibility criteria
Have conditions other than atrial fibrillation that require oral anti-coagulation
Have had a stroke within the past 7 days
Have a hypersensitivity to edoxaban
Have moderate or severe mitral stenosis
Be required to take aspirin at a dose of 81mg or more a day
Have an unsuccessful LAA closure
Be planning to have another surgery or invasive procedure within 6 of enrollment
Edoxaban is currently approved by the FDA to prevent blood clots in patients with non-valvular atrial fibrillation, and may have a reduced risk of bleeding compared to other approved drugs.
All patients will receive Edoxaban for 6 weeks and if the LAA closure is deemed acceptable, will stop taking edoxaban and will be prescribed aspirin and clopidogrel until their routine 6 month visit.